Antipsychotic Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the antipsychotic drugs market size is expected to grow from USD 20.10 billion in 2025 to USD 21.35 billion in 2026 and is forecast to reach USD 28.88 billion by 2031 at 6.22% CAGR over 2026-2031.

This report is Segmented by Drug Class (First Generation, Second Generation, and Third Generation), Application (Schizophrenia, Bipolar Disorder, Major Depressive Disorder, and More), Route of Administration (Oral and Injectables), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Antipsychotic Drugs Market Trends and Insights

Rising LAI Adoption in Community Mental-Health Programs

Long-acting injectable antipsychotics are closing the 50% non-adherence gap that undermines oral therapy. A 2024 Journal of Clinical Psychopharmacology study reported 30-day readmission rates of 1.9% for LAIs versus 8.3% for oral drugs, translating to a 77% reduction in early rehospitalizations. Early initiation of LAIs within 12 months of diagnosis yields annual healthcare savings of USD 7,195 per patient by reducing emergency department utilization. These findings persuade payers to reimburse LAIs earlier in treatment algorithms, accelerating penetration across community clinics.

Expanding Early-Psychosis Intervention Centers

Coordinated Specialty Care programs are scaling rapidly. The National Alliance on Mental Illness estimates that broader roll-out could reach 600,000-800,000 additional patients and generate USD 115-140 billion in system savings over a decade . A 2024 Hong Kong study in JAMA Network Open linked implementation of the EASY Plus model to steep declines in self-harm episodes among adults aged 26-44 years. These centers favor newer agents with balanced efficacy and tolerability profiles, fuelling demand for third-generation options.

Patent Cliffs of Key Atypical Molecules

Major brands face imminent loss of exclusivity. Abilify Maintena's patent expiry in June 2025 threatens 44% of its prescription base. Johnson & Johnson's Invega Sustenna posted USD 2.9 billion in 2023 U.S. sales, yet generics from Teva and Viatris loom. Price erosion depresses branded revenue and compresses margins across the antipsychotic drugs market.

Other drivers and restraints analyzed in the detailed report include:

1. Surge in Medicaid/Medicare Coverage for Third-Generation Agents
2. Digital-Therapeutic Companion Apps Boosting Medication Adherence
3. Addiction Caused Due to the Antipsychotic Drugs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Atypical formulations generated the largest antipsychotic drugs market size in 2025, capturing 72.38% revenue on the back of broad indications and payer familiarity. Third-generation agents, though smaller in absolute dollars, are forecast to outpace the overall market with a 6.96% CAGR through 2031. Their dopamine-partial-agonist or dual muscarinic activity mitigates extrapyramidal side effects, a clear advantage that bolsters clinician confidence. Bristol Myers Squibb's Cobenfy (xanomeline-trospium), the first new mechanistic class in 70 years, underscores this pivot.

Improved metabolic profiles and reduced tardive-dyskinesia risk strengthen payer value propositions. The antipsychotic drugs market size attached to third-generation products is predicted to expand steadily as pipeline entrants such as roluperidone advance toward possible approval. First-generation agents remain useful in acute agitation and resource-strained settings, yet their share declines annually due to tolerability concerns.

Complete Report Scope:

• By Drug Class
  • Typical (First-Generation) Antipsychotics
  • Atypical (Second-Generation) Antipsychotics
  • Dopamine Partial Agonists (Third-Generation)
• By Therapeutic Application
  • Schizophrenia
  • Bipolar Disorder
  • Major Depressive Disorder
  • Dementia-Related Psychosis
  • Others
• By Route of Administration
  • Oral
  • Injectables
    • Long-Acting Injectables (LAIs)
    • Short-Acting Injectables
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 39.22% of global revenue in 2025, buoyed by early adoption of third-generation agents and payer reforms that cap annual patient out-of-pocket spend at USD 2,000 under Medicare Part D cms.gov. FDA approvals for muscarinic-receptor therapies and once-bimonthly LAIs sustain clinical enthusiasm, while Canada and Mexico add incremental growth through mental-health investment schemes.

Asia-Pacific is the fastest-growing territory at a 7.61% CAGR through 2031. China's domestic innovators secured the first U.S. nod for a Chinese-developed paliperidone palmitate LAI in 2024, spotlighting the region's research ascent. Improved insurance penetration and destigmatization campaigns in India and Southeast Asia enlarge the treated population, further propelling the antipsychotic drugs market.

Europe retains solid share anchored by universal health coverage and a regulatory focus on real-world evidence. The 2025 approval of Rxulti for adolescent schizophrenia widens access in a sensitive demographic. Price-volume agreements temper list-price inflation, yet offsetting uptake of novel therapies supports steady value growth. South America and the Middle East & Africa, though smaller, are forecast to out-perform historic averages as governments integrate mental-health services into national benefit packages.

1. Eli Lilly and Company
2. AstraZeneca
3. Johnson & Johnson
4. Abbott Laboratories
5. Pfizer
6. Nova Biomedical
7. Otsuka
8. Luye Pharma
9. Nihon Kohden
10. Bristol-Myers Squibb
11. Grifols
12. Arkray
13. Acadia Pharmaceuticals
14. Convergent Technologies
15. EKF Diagnostics
16. PHC Holdings (Ascensia)
17. WerfenLife Diagnostics China
18. Edan Instruments
19. Sphere Medical
20. Brolis Sensor Technology

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support